RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hansa Biopharma - Stock

Hansa Biopharma Revenue 2024

Hansa Biopharma Revenue

257.21 M SEK

Ticker

HNSA.ST

ISIN

SE0002148817

WKN

A0M65T

In 2024, Hansa Biopharma's sales reached 257.21 M SEK, a 91.81% difference from the 134.09 M SEK sales recorded in the previous year.

The Hansa Biopharma Revenue history

YEARREVENUE (undefined SEK)GROSS MARGIN (%)
2029e4.581,55
2028e1.744,07
2027e0.917,83
2026e0.5812,16
2025e0.3520,16
2024e0.2627,58
20230.1352,91
20220.1575,10
20210.0354,47
20200.0183,65
2019074,26
2018072,72
2017093,58
2016091,59
20150.0190,14
2014094,70
20130-569,36
20120-344,66
20110-1403,08
20100-335,73
20090-346,31
20080-11350,00
2007--

Hansa Biopharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Hansa Biopharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hansa Biopharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hansa Biopharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Hansa Biopharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Hansa Biopharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Hansa Biopharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hansa Biopharma’s growth potential.

Hansa Biopharma Revenue, Profit, and EBIT History

DateHansa Biopharma RevenueHansa Biopharma EBITHansa Biopharma Net Income
2029e4.58 B SEK0 SEK1.59 B SEK
2028e1.74 B SEK211.32 M SEK105.49 M SEK
2027e906.25 M SEK-251.68 M SEK-233.57 M SEK
2026e583.44 M SEK-436.03 M SEK-388.94 M SEK
2025e351.86 M SEK-571.84 M SEK-575.03 M SEK
2024e257.21 M SEK-600.56 M SEK-701.16 M SEK
2023134.09 M SEK-791.16 M SEK-831.72 M SEK
2022154.53 M SEK-576.12 M SEK-611.13 M SEK
202133.88 M SEK-539.58 M SEK-548.28 M SEK
20206.1 M SEK-422.81 M SEK-420.85 M SEK
20193.36 M SEK-357.6 M SEK-360.01 M SEK
20183.36 M SEK-246.5 M SEK-247.97 M SEK
20173.44 M SEK-176.08 M SEK-176.66 M SEK
20162.58 M SEK-111.14 M SEK-111.13 M SEK
20156.68 M SEK-66.2 M SEK-66.27 M SEK
20144.72 M SEK-24.71 M SEK-29.04 M SEK
20131.73 M SEK-17.64 M SEK-17.56 M SEK
20122.62 M SEK-16.81 M SEK-16.47 M SEK
20111.3 M SEK-24.46 M SEK-24.57 M SEK
20104.45 M SEK-19.99 M SEK-18.84 M SEK
20092.98 M SEK-15.74 M SEK-15.81 M SEK
2008100,000 SEK-15.91 M SEK-2.56 M SEK
20070 SEK-3.64 M SEK-2.47 M SEK

Hansa Biopharma stock margins

The Hansa Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hansa Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hansa Biopharma.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Hansa Biopharma's sales revenue. A higher gross margin percentage indicates that the Hansa Biopharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Hansa Biopharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Hansa Biopharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hansa Biopharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hansa Biopharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hansa Biopharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Hansa Biopharma Margin History

Hansa Biopharma Gross marginHansa Biopharma Profit marginHansa Biopharma EBIT marginHansa Biopharma Profit margin
2029e52.91 %0 %34.82 %
2028e52.91 %12.12 %6.05 %
2027e52.91 %-27.77 %-25.77 %
2026e52.91 %-74.74 %-66.66 %
2025e52.91 %-162.52 %-163.43 %
2024e52.91 %-233.49 %-272.6 %
202352.91 %-590 %-620.25 %
202275.1 %-372.83 %-395.49 %
202154.47 %-1,592.72 %-1,618.4 %
202083.65 %-6,933.54 %-6,901.49 %
201974.26 %-10,630.05 %-10,701.81 %
201872.72 %-7,340.62 %-7,384.57 %
201793.58 %-5,115.72 %-5,132.48 %
201691.59 %-4,309.23 %-4,309 %
201590.14 %-991.78 %-992.75 %
201494.7 %-523.52 %-615.25 %
2013-569.36 %-1,019.65 %-1,015.03 %
2012-344.66 %-641.6 %-628.63 %
2011-1,403.08 %-1,881.54 %-1,890 %
2010-335.73 %-449.21 %-423.37 %
2009-346.31 %-528.19 %-530.54 %
2008-11,350 %-15,910 %-2,560 %
200752.91 %0 %0 %

Hansa Biopharma Aktienanalyse

What does Hansa Biopharma do?

Hansa Biopharma AB is a Swedish biotechnology company specializing in the development of therapy options for rare immune and inflammatory diseases. The company was founded in Lund in 1986 and now has branches in the USA and Japan. The company's business model and divisions include clinical development, corporate development, and production. The clinical development division focuses on conducting clinical studies to demonstrate the effectiveness and safety of new drugs. The corporate development division handles collaboration with regulatory authorities, investors, and other partners. The production division encompasses the manufacturing of products developed by Hansa Biopharma AB. The company's products include Idefirix, an antibody-based drug candidate for the treatment of severe hemolysis due to alloimmune blood group antibodies, and an immunoglobulin production technology platform for the development of antibody therapies for various diseases. Hansa Biopharma AB's roots date back to 1986 when it was established as a spin-off from Lund University. Initially, the company focused on the development and production of diagnostics and reagents for immunology and clinical chemistry. In recent years, it shifted its focus to developing innovative therapies for rare immune and inflammatory diseases. In 2010, the company made a breakthrough with the discovery of the 174H target, which led to the development of Idefirix. Idefirix has since successfully completed phase III clinical trials and may soon be approved for the treatment of severe hemolysis. In conclusion, Hansa Biopharma AB is a leading biotechnology company with a strong vision and clear strategy for developing innovative therapies for rare immune and inflammatory diseases. The company specializes in antibody therapies and is currently focused on the development of Idefirix and the expansion of its immunoglobulin production technology platform. With a strong research pipeline and experienced management team, Hansa Biopharma AB is well-positioned to make significant progress in the coming years and develop innovative therapies for patients with rare diseases. Hansa Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Hansa Biopharma's Sales Figures

The sales figures of Hansa Biopharma originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Hansa Biopharma’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Hansa Biopharma's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Hansa Biopharma’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Hansa Biopharma Stock

How much revenue did Hansa Biopharma generate this year?

Hansa Biopharma has achieved a revenue of 257.21 M SEK this year.

How much was the turnover of the company Hansa Biopharma compared to the previous year?

The revenue of Hansa Biopharma has increased by 91.81% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Hansa Biopharma?

The revenue of Hansa Biopharma is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Hansa Biopharma measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Hansa Biopharma so important for investors?

The revenue of Hansa Biopharma is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Hansa Biopharma pay?

Over the past 12 months, Hansa Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hansa Biopharma is expected to pay a dividend of 0 SEK.

What is the dividend yield of Hansa Biopharma?

The current dividend yield of Hansa Biopharma is .

When does Hansa Biopharma pay dividends?

Hansa Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hansa Biopharma?

Hansa Biopharma paid dividends every year for the past 0 years.

What is the dividend of Hansa Biopharma?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hansa Biopharma located?

Hansa Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hansa Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hansa Biopharma from 6/19/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.

When did Hansa Biopharma pay the last dividend?

The last dividend was paid out on 6/19/2024.

What was the dividend of Hansa Biopharma in the year 2023?

In the year 2023, Hansa Biopharma distributed 0 SEK as dividends.

In which currency does Hansa Biopharma pay out the dividend?

The dividends of Hansa Biopharma are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hansa Biopharma

Our stock analysis for Hansa Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hansa Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.